Deal Bristol Myers Squibb deal · amount not disclosed · announced Nov 12, 2025 Company release ↗Source quote
Nov 12, 2025 · Company release ↗ “Octant Enters Research Collaboration with Bristol Myers Squibb to Discover Novel Small Molecules for Neurodegenerative Diseases”
Trial start 1: A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) source ↗
Upcoming milestones
Nov 1, 2028 (ESTIMATED) · 1 · A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · NCT07408232
Estimated primary completion per ClinicalTrials.gov. Dates move.
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
1
Recruiting
Mar 10, 2026
Nov 1, 2028 (estimated)
NIH awards 2
Annual award amounts. Total $564K.
NIH award 1R43TR003567-01 FY2021: $316,638 awarded for that fiscal year; activity R43 (SBIR); PI FISCHER, CURT R.; recipient as written: OCTANT, INC., EMERYVILLE, CA. High-throughput chemical screens for GPCR functio source ↗
NIH award 1R43GM137745-01 FY2020: $246,943 awarded for that fiscal year; activity R43 (SBIR); PI KOSURI, SRIRAM; recipient as written: OCTANT, INC., EMERYVILLE, CA. Functional Genomics of G Protein-Coupled Receptors source ↗
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
